Systematic, randomised atrial fibrillation screening using detailed phenotyping with a risk-prediction model combined with patch electrocardiogram in a Swedish population aged 65 years or older: The CONSIDERING-AF trial
Europace · 22.08.2025
DOI: 10.1093/europace/euaf190 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Europace, online erschienen am 22.08.2025. Verfasst von Emelie Rakai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Entrévägen 2, 182 88 Stockholm, Sweden. Hauptthemen laut MEDLINE: Atrial Fibrillation, Electrocardiography, Mass Screening, Machine Learning. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb, Pfizer Alliance.
Abstract (Originalsprache)
Background and aims Atrial fibrillation (AF), often asymptomatic and underdiagnosed, is an independent risk factor for ischemic stroke. A knowledge gap remains regarding the optimal target population, and method to use for AF screening. We aimed to test whether screening for AF using a machine learning-based risk-prediction model (RPM) and 14-day continuous patch electrocardiogram (ECG) (Philips ePatch) in high-risk individuals ≥65 years is more effective than standard care.
Methods
Individuals ≥65 years were assigned to general or RPM cohort. The general cohort was randomised to control or invitation. In the RPM cohort, high-risk individuals, identified by RPM, were randomised to control or invitation. The primary outcome was six-month AF incidence, analysed as intention-to-invite, comparing RPM + invitation with general + control.
Results
Of 2,960 randomised individuals, participation was 43% (632/1480) in invitation arms. AF incidence was higher in RPM + invitation than in general + control arm (3.8%, 28/740 versus 0.7%, 5/740; p<0.001), yielding a risk ratio of 5.6, (95% confidence interval [2.2, 14.4]), and a number needed to invite of 32. AF was more often detected in RPM + invitation than in general + invitation arm (1.1%, 8/740; p<0.001), but not more often than in RPM + control arm (2.2%, 16/740; p=0.07). No difference was found between general + invitation and general + control arms (1.1%, 8/740 versus 0.7%, 5/740; p=0.40).
Conclusion
Among high-risk individuals ≥65 years, the combination of a machine learning-based risk-prediction model and long-term ECG recording was superior to standard care in identifying new AF cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Entrévägen 2, 182 88 Stockholm, Sweden.
- Department of Medicine, Halland Hospital Varberg, Varberg, Sweden, Träslövsvägen 68, 432 81 Varberg, Sweden.
- Research and Innovation Centre, Region Halland, Halmstad, Sweden.
- Center for Applied Intelligent Systems Research in Health (CAISR Health), Halmstad University, Halmstad, Sweden.
- Bristol Myers Squibb AB, Solna, Sweden.
- Pfizer AB, Stockholm, Sweden.
ORCID-Profile: Emelie Rakai, Farzaneh Etminani, Anton Andersson, Torbjörn Vik, Stefan Kunkel, Johan Holm, Angelo Modica, Helena M Linge, Manish Wadhwa, Johan Engdahl, Emma Sandgren
Förderung
- Bristol Myers Squibb
- Pfizer Alliance
Zitieren
APA
Rakai, E., Etminani, F., Younan, N., Andersson, A., Andersson, M., Vik, T., Kunkel, S., Sundin, A., Holm, J., Modica, A., Linge, H. M., Parikh, P., Wadhwa, M., Engdahl, J., & Sandgren, E. (2025). Systematic, randomised atrial fibrillation screening using detailed phenotyping with a risk-prediction model combined with patch electrocardiogram in a Swedish population aged 65 years or older: The CONSIDERING-AF trial. Europace. https://doi.org/10.1093/europace/euaf190
Vancouver
Rakai E, Etminani F, Younan N, Andersson A, Andersson M, Vik T, et al. Systematic, randomised atrial fibrillation screening using detailed phenotyping with a risk-prediction model combined with patch electrocardiogram in a Swedish population aged 65 years or older: The CONSIDERING-AF trial. Europace. 2025. doi:10.1093/europace/euaf190
BibTeX
@article{Rakai2025,
author = {Rakai, Emelie and Etminani, Farzaneh and Younan, Ninia and Andersson, Anton and Andersson, Maria and Vik, Torbjörn and Kunkel, Stefan and Sundin, Anna and Holm, Johan and Modica, Angelo and Linge, Helena M and Parikh, Purvee and Wadhwa, Manish and Engdahl, Johan and Sandgren, Emma},
title = {Systematic, randomised atrial fibrillation screening using detailed phenotyping with a risk-prediction model combined with patch electrocardiogram in a Swedish population aged 65 years or older: The CONSIDERING-AF trial},
journal = {Europace},
year = {2025},
doi = {10.1093/europace/euaf190}
}
EUVIMED